In a 39‑year‑old patient with primary focal segmental glomerulosclerosis, how should oral prednisolone be started, what dose and duration, and how should the taper be performed?

Treatment Protocol for Primary FSGS with Prednisolone in a 39-Year-Old Patient

Start prednisolone at 1 mg/kg/day (maximum 80 mg daily) as a single morning dose, continue for at least 4 weeks and up to 16 weeks maximum until complete remission is achieved, then taper by 5 mg every 1-2 weeks to complete a total 6-month course. 1

Starting Dose and Initial Treatment Phase

Begin with prednisolone 1 mg/kg/day (capped at 80 mg) as a single daily dose. Alternatively, you can use an alternate-day regimen of 2 mg/kg (maximum 120 mg), though daily dosing is more commonly used 1.

Duration of high-dose therapy:

• Continue the full dose for minimum 4 weeks
• Extend up to maximum 16 weeks if needed
• Stop high-dose phase when complete remission occurs (whichever comes first) 1

Critical Monitoring Points During High-Dose Phase

Expect proteinuria reduction by 4-8 weeks if the patient will respond 1. If you see absolutely no improvement in proteinuria by 8 weeks AND the patient is experiencing significant steroid side effects, strongly consider stopping steroids early and switching to calcineurin inhibitors rather than persisting the full 16 weeks 1.

The KDIGO 2021 guidelines explicitly acknowledge that oral prednisolone at 1 mg/kg/day carries severe toxicity potential, requiring close supervision throughout treatment 1.

Tapering Protocol

If Complete Remission Achieved Rapidly

• Continue high-dose prednisolone for 4 weeks AFTER proteinuria disappears (or 4 weeks total, whichever is longer)
• Then reduce by 5 mg every 1-2 weeks
• Complete the taper to reach a total treatment duration of 6 months from start 1

If Partial Remission at 8-12 Weeks

• Continue high-dose therapy until week 16 to assess for further improvement
• Then reduce by 5 mg every 1-2 weeks
• Complete taper to reach total 6-month duration 1

If Steroid-Resistant or Significant Toxicity

• Rapidly taper steroids as tolerated
• Switch to calcineurin inhibitor (cyclosporine 3-5 mg/kg/day in 2 divided doses OR tacrolimus 0.05-0.1 mg/kg/day in 2 divided doses) 1

Practical Example for Your 39-Year-Old Patient

Assuming the patient weighs 70 kg:

• Starting dose: 70 mg prednisolone daily (single morning dose)
• Week 0-4: 70 mg daily, monitor proteinuria closely
• Week 4-8: Continue 70 mg if showing response; if no response by week 8, consider switching to CNI
• Week 8-16: Continue 70 mg only if partial response and tolerating well
• After remission or week 16: Begin taper
  • Week 17-18: 65 mg daily
  • Week 19-20: 60 mg daily
  • Week 21-22: 55 mg daily
  • Continue reducing 5 mg every 1-2 weeks until reaching 6 months total duration

Important Caveats

Before starting steroids, confirm this is truly primary FSGS:

• Exclude secondary causes (obesity, medications, viral infections, genetic forms)
• Confirm nephrotic syndrome (proteinuria >3.5 g/day AND albumin <30 g/L) 1
• Consider genetic testing in adults to exclude genetic forms that won't respond to immunosuppression 1

Common pitfall: Starting steroids in genetic or secondary FSGS wastes time and exposes patients to toxicity without benefit. The KDIGO guidelines emphasize that immunosuppression should only be used in primary FSGS with full nephrotic syndrome 1.

Steroid-sparing alternatives: Recent meta-analysis data suggests that for patients at high risk of steroid complications, mycophenolate mofetil combined with lower-dose steroids or leflunomide combined with steroids may offer reasonable alternatives, though the evidence quality is lower than for high-dose steroids alone 2.

Response rates: Approximately 50% of adult FSGS patients are steroid-resistant 3. Age and baseline creatinine are independent predictors of poor outcome 4. Your 39-year-old patient has a reasonable chance of response if kidney function is preserved at baseline.